ABBVIE +1% in after after hours
Galapagos Arthritis Treatment Meets Endpoints in Study
2015-04-14 20:14:28.793 GMT
By Jim Silver
(Bloomberg) -- Treatment with filgotinib for rheumatoid
arthritis met key endpoints after 12 weeks of treatment as add-
on to methotrexate in Phase 2B study, co. says.
* Study achieved primary endpoint with statistically
significant improvement in ACR20 score vs placebo
* Expects to report full 24-week results for the study around
midyear
* Conf. call Wednesday, 4pm CET, also webcast; details in
statement
Link to Statement:Link
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Jim Silver in New York at +1-212-617-7342 or
jsilver@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net
Jim Silver
2015-04-14 20:14:28.793 GMT
By Jim Silver
(Bloomberg) -- Treatment with filgotinib for rheumatoid
arthritis met key endpoints after 12 weeks of treatment as add-
on to methotrexate in Phase 2B study, co. says.
* Study achieved primary endpoint with statistically
significant improvement in ACR20 score vs placebo
* Expects to report full 24-week results for the study around
midyear
* Conf. call Wednesday, 4pm CET, also webcast; details in
statement
Link to Statement:Link
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Jim Silver in New York at +1-212-617-7342 or
jsilver@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net
Jim Silver